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 11 
ABSTRACT 12 
Human male reproductive disorders (cryptorchidism, hypospadias, testicular cancer and low 13 
sperm counts) are common and some may be increasing in incidence worldwide. These 14 
associated disorders can arise from subnormal testosterone production during fetal life. This 15 
has resulted in a focus on in-utero environmental influences that may result in reproductive 16 
effects on the offspring in later life. Over recent years, there has been a dramatic increase in 17 
the scientific literature describing associations between in-utero environmental exposures 18 
(e.g. industrial chemicals and pharmaceuticals) and subsequent reproductive outcomes in 19 
male offspring. This includes studies investigating a potential role for in-utero analgesic 20 
exposure(s) on the fetal testis; however, providing definitive evidence of such effects 21 
presents numerous challenges. In this review, we describe an approach to assessing the 22 
potential clinical relevance of in-utero (and postnatal) environmental exposures on 23 
subsequent male reproductive function using exposure to the analgesic paracetamol as an 24 
example. 25 
 26 
 27 
28 
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Male Reproductive Disorders and Testicular Dysgenesis Syndrome 29 
  30 
From the mid 1900's to the present date, many studies have reported evidence for an 31 
increasing secular trend in the most common male reproductive abnormalities including 32 
hypospadias, cryptorchidism, low sperm counts
1-5
 and testicular germ cell cancer (TGCC)
6-10
. 33 
Over the past 30 years, the incidence of TGCC has increased substantially
10
 and 34 
epidemiological studies predict that the incidence in Europe will increase by a further 24% 35 
by 2025
9 11
.  36 
 37 
The term ‘testicular dysgenesis syndrome’ (TDS) is often used to describe this group of 38 
individual disorders due o their frequent association and their relationship to impaired 39 
androgen production/action during fetal life. Genetic causes of impaired androgen action 40 
include androgen insensitivity syndrome (AIS), caused by a mutation in the androgen 41 
receptor in XY individuals, which results in under-masculinisation of the external genitalia, 42 
which can result in a typical female appearance in the complete (CAIS) form. AIS also 43 
includes features consistent with TDS (hypospadias, cryptorchidism, infertility and an 44 
increased risk of TGCC)
12 13
. Although it is clear that many TDS disorders can arise as a result 45 
of genetic abnormalities, there is increasing evidence that in-utero environmental factors 46 
(including lifestyle and chemical exposures) may also play a role (Figure 1)
3 14 15
 
16
.  47 
 48 
Studies in rodents have demonstrated that perturbation of androgen production/action 49 
during fetal life results in the development of TDS disorders in male offspring
17-22
. These 50 
studies involve in-utero exposure to a plasticising agent (Di-n-butyl phthalate; DBP) which 51 
results in subsequent cryptorchidism, hypospadias, impaired spermatogenesis and primary 52 
hypogonadism. Crucially, there is a critical window of sensitivity in fetal life, termed the 53 
‘masculinisation programming window’ (MPW), during which the subsequent development 54 
of these disorders may be programmed by lack of androgen production or action
19
. The 55 
MPW has been shown to occur between embryonic day (e)15.5 – e18.5 in rats and has been 56 
estimated to correspond to 8-14 weeks of gestation in humans
19 22
.  57 
 58 
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One of the challenges in understanding the development of these disorders in humans has 59 
been the assessment of fetal androgen exposure in male offspring. Measurement of 60 
anogenital distance (AGD), which is sexually dimorphic, can be used as a biomarker/read-61 
out of fetal androgen exposure, and thus are a proxy for anti-androgenic effects of in-utero 62 
exposures
23-25
 that can be utilised throughout life
25 26
. AGD is reduced in boys presenting 63 
during the neonatal period with cryptorchidism and/or hypospadias
27
 and in adulthood, 64 
AGD has been shown to be positively associated with semen quality
28 29
 and serum 65 
testosterone
23
. It should be emphasised that whilst measuring AGD can be used for carefully 66 
conducted population-based studies, technical difficulties, in terms of accuracy of 67 
measurement, reproducibility and time required to conduct this examination, limit its utility 68 
for clinical assessment of individuals.  69 
 70 
The association between events that occur during fetal life and the development of male 71 
reproductive disorders, combined with the evidence to suggest a role for environmental 72 
influences has resulted in a large number of epidemiological and experimental studies 73 
investigating a range of chemical and pharmaceutical exposures. Recently a number of 74 
studies have described a potential role for analgesics in the development of these 75 
disorders
30-40
. In order to describe the potential effects of in-utero exposure to analgesics on 76 
male reproductive development we will first discuss in detail the development of the testis 77 
from fetal life focusing on cellular events that determine testosterone production and germ 78 
cell development. We will then briefly describe the approach to assessing in-utero 79 
environmental exposures before describing in detail the potential effects of paracetamol 80 
(the most commonly used analgesic worldwide) exposure during pregnancy, on male 81 
reproductive health in the offspring and subsequent generation(s).  82 
 83 
 84 
Testicular Development and Function during Fetal and Early 85 
Postnatal Life 86 
 87 
Formation of the testis 88 
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In order to understand the potential for in-utero exposures to affect the developing testis, it 89 
is important to understand testicular cellular development and function during fetal life and 90 
the early postnatal period (Figure 2). Primordial germ cells (PGCs) emerge at 4-5wks post 91 
conception in the human, and migrate from the yolk sac into the genital ridge where they 92 
become known as gonocytes
41
. Interaction between gonocytes and the stromal 93 
microenvironment, along with the presence of a single transcription factor coded by the Y 94 
chromosome, sex-determining region Y protein (SRY), determines gonadal sex. Following 95 
SRY expression, gonadal somatic cells, arising from the coelomic epithelium, begin to 96 
differentiate into Sertoli cells (SC)
42
. SC aggregate in a layer around gonocytes, thus forming 97 
the seminiferous cords at approximately 6-7 gestational weeks in the human (or e13 in the 98 
mouse)
43 44
. The seminiferous cords separate the seminiferous epithelium, consisting solely 99 
of germ cells and SC, from the interstitial compartment, which includes the testosterone-100 
secreting fetal Leydig cell population
45
. 101 
 102 
Sertoli cell (SC) development and function 103 
SC play a vital role in supporting spermatogenesis in the adult testis. The total number of SC 104 
in adulthood determines final testis size, number of germ cells and maximum sperm 105 
output
46 47
 
48
. However, SC also have important functions in fetal life including secretion of 106 
anti-Müllerian Hormone (AMH), necessary for regression of the Müllerian ducts, and factors 107 
(e.g. Desert Hedgehog) which induce fetal Leydig cell differentiation
49-52
. SC proliferation in 108 
humans occurs during fetal and neonatal life followed by a quiescent period until the 109 
second proliferative wave around puberty
48
. The switch from pre-puberty to puberty 110 
triggers the final maturation from proliferative immature SC to non-mitotic mature SC 111 
capable of supporting spermatogenesis (Figure 2). Rodent studies have indicated that 112 
prenatal exposures to plasticising chemicals known as phthalates can arrest SC development 113 
in their immature state, thus interfering with spermatogenesis
18 21
 and foci of immature SC 114 
are also a common feature in infertile men with azoospermia and other TDS disorders
21 53
.  115 
 116 
Germ cell development and fertility 117 
During fetal and early postnatal life, the germ cells differentiate from gonocytes into 118 
spermatogonia during which they cease to express pluripotency markers (e.g. OCT4, Nanog) 119 
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and begin to express germ cell-specific spermatogonial proteins (dDX4, MAGE-A4), a process 120 
that occurs asynchronously in humans from late second trimester to ~6 months 121 
postnatally
54
. This period of germ cell development is important in establishing the 122 
spermatogonial stem cell pool, not only for future fertility but also because failure of 123 
gonocytes to differentiate into spermatogonia during fetal/early postnatal life is thought to 124 
result in germ cell neoplasia in-situ (GCNIS), which is the pre-malignant step towards TGCC 125 
in adulthood
55
 (Figure 2). In addition to the increased risk of TGCC, individuals with TDS 126 
disorders may also exhibit dysgenetic areas in the testis in which germ cells are lost and 127 
seminiferous tubules become Sertoli cell-only (SCO). Therefore, environmental influences 128 
that impair germ cell development during fetal and early postnatal life may result in 129 
reduced fertility and/or the development of TGCC
16
.  130 
 131 
Leydig cell development and function 132 
Leydig cells (LC) are essential for endocrine function of the testis as they produce the steroid 133 
hormone testosterone. Testosterone is primarily required for fetal masculinisation 134 
(including testicular descent), pubertal development and spermatogenesis. LC development 135 
in the human is considered a 'triphasic event', as demonstrated by the peaks in plasma 136 
testosterone levels across the life course that coincide with the development of separate 137 
lineages of LC (Figure 2). A fetal LC population is present from 6 weeks gestation in humans 138 
(e12.5 in the mouse)
56-59
.
 
By 2-3 months of postnatal life, a neonatal population is evident, 139 
responsible for the so-called ‘mini-puberty’
60
 and finally, an adult LC population arises at 140 
puberty and remains throughout adulthood
61
. Placental hCG initially stimulates testosterone 141 
production from the fetal LC and insufficiency in the former is associated with hypospadias 142 
and cryptorchidism
62
, whereas during the neonatal period, LH is responsible for stimulating 143 
the peak in plasma testosterone levels
63 64
. In rodents, perturbations of fetal testosterone 144 
production (e.g. due to phthalate exposure) may result in some TDS disorders, including 145 
Leydig cell hyperplasia
62
 and has also been shown to be associated with primary 146 
hypogonadism/compensated LC failure in adulthood
20 21
. Insulin-like factor 3 (Insl3) is 147 
another hormone produced by the Leydig cell which, like testosterone, plays a crucial role in 148 
testicular descent. Perturbations in Insl3 during the fetal period can also result in 149 
cryptorchidism in rodents
65 66
. 150 
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Assessing the Impact of Environmental Exposures on Human Health  151 
 152 
Studies aimed at investigating the impact of environmental exposures on human health 153 
largely consist of epidemiological studies in human populations and experimental animal 154 
studies. Whilst epidemiological evidence can demonstrate associations between exposures 155 
and occurrence of a condition, experimental studies can imply causation and demonstrate 156 
potential mechanisms. Critical assessment of the literature on effects of environmental 157 
exposures must take into account the strengths and limitations of these approaches (Table 158 
1). We will describe the epidemiological and experimental evidence in relation to 159 
paracetamol exposure and the development of male reproductive disorders and in doing so 160 
we will illustrate some of the factors that need to be considered in order to critically assess 161 
such studies.   162 
 163 
 164 
Effects of Exposure to Paracetamol on Male Reproductive Health 165 
 166 
Maternal use of paracetamol during pregnancy 167 
Avoidance of pain and pyrexia during pregnancy is important for fetal and maternal health 168 
and analgesics play an important role in the treatment of pain and pyrexia during 169 
pregnancy. In a large study of pregnant women from Europe, US and Australia (n=9,459), 170 
81.2% reported taking over-the-counter (OTC) medicines
67
. It is reported that >50% of 171 
pregnant women in the US take OTC analgesics, including paracetamol
68 69
. Studies in the UK 172 
of self-reported medication use have shown that paracetamol is the most commonly used 173 
OTC medication during pregnancy, with 36% of pregnant women reporting paracetamol 174 
intake during the 1st trimester (n= 465/1305)
70
 and 54% during the first 20 weeks of 175 
gestation
71
. In a similar Danish study, 47% of mothers reported taking paracetamol at some 176 
point during their pregnancy
30
. Paracetamol readily crosses the placental barrier with a 177 
mean half-life of approximately 3 hours
72 73
 and its serum concentration is equivalent 178 
between mother and fetus following an oral therapeutic dose (1g)
74
. The number  of 179 
epidemiological and experimental studies into the potential relationship between analgesic 180 
exposure and male reproductive disorders have been increasing over recent years
31
.  181 
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Epidemiology of paracetamol exposure and male reproductive function 182 
Epidemiological studies have reported associations between maternal use of analgesics and 183 
cryptorchidism in resulting male offspring
30 32 33 75
; however, this is not consistent across all 184 
studies
34
. Where associations exist, they appear to be restricted to exposure during the 2
nd
 185 
trimester or following prolonged exposure
35
. The timing of exposure in relation to the 186 
critical period for programming male reproductive development is likely to be important. 187 
One study has reported an association between cryptorchidism and paracetamol exposure 188 
during the human MPW (estimated to be 8-14 gestational weeks
19
), however importantly, 189 
this was only statistically significant for prolonged exposure of >4 weeks
32
.  190 
 191 
The reported association between exposure to paracetamol and cryptorchidism could be 192 
explained by a reduction in androgen (testosterone) production by the human fetal testis, 193 
and anogenital distance (AGD) has been shown to represent an ‘indirect’ postnatal 194 
readout of androgen exposure during fetal life
24
. A recent prospective birth cohort study 195 
showed that 40% of women reported using paracetamol during the first 28 weeks of 196 
pregnancy
36
. Exposure to a mixture of mild analgesics (including paracetamol and 197 
NSAIDS) was negatively associated with AGD in male infants (n=20; 3 months) which 198 
suggests reduced androgen signalling during fetal life. However, these results do not 199 
show a paracetamol-only induced effect and this may highlight the importance of 200 
exposure to ‘mixtures’ potentially resulting in additive effects which may be more 201 
representative of analgesic intake during pregnancy
36
. A similar study (n=434 male 202 
infants) reported an association between paracetamol exposure and reduced AGD from 203 
birth to 2 years which was independent of body size
37
 and interestingly, this association 204 
was limited to paracetamol exposure during the proposed human MPW (i.e. 1
st
 205 
trimester). Importantly, all of the above epidemiological studies are based on self-reporting 206 
of analgesic use, determined in most cases by the use of retrospective questionnaires. The 207 
possibility of inaccurate recall or recall bias and lack of direct measurements of analgesic 208 
exposure are important limitations of these studies. 209 
 210 
 211 
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Experimental approach to assessing the effect of paracetamol exposure during fetal life on 212 
male reproductive function 213 
A variety of experimental approaches have been utilised to determine the effect of 214 
paracetamol exposure on the fetal testis, particularly in relation to testosterone production. 215 
This includes in-vivo approaches in pregnant rodents
30 38
 
76 77
 and in-vitro studies using fetal 216 
testis tissues from rodents
30 78
 and humans
39
. Recently, a xenografting approach has been 217 
developed which can assess the effects of exposures on the human fetal testis in a more 218 
physiological manner than can be achieved in vitro
38
.  219 
 220 
To investigate potential paracetamol-induced effects during fetal life, pregnant rats were 221 
exposed to doses of 150, 250 or 350 mg/kg/day from e13-21. AGD was reduced in male 222 
offspring compared to untreated controls
30
 with similar effects on AGD described in other 223 
studies
38
 
77
. However, a recent study using the same regimen as described above (350 224 
mg/kg/day from e13-21) did not demonstrate a significant effect on AGD
76
. The timing of 225 
exposure in these studies coincides with the MPW; however, the doses (150-350mg/kg/d) 226 
used are higher than therapeutic doses (~60mg/kg/d) to which humans are usually 227 
exposed
38
. There are also likely to be large differences in the pharmacokinetics and 228 
metabolism of these agents in rodents compared to humans, making direct correlations 229 
from dose effects between species challenging.  230 
 231 
In-vitro paracetamol exposure studies have also been described using fetal rat testis 232 
explants (e14.5) cultured for 3 days in media containing paracetamol (1μM)
30 78
. This 233 
resulted in a significant reduction in testosterone production, even at a concentration of 234 
1μM, which is well below the therapeutic concentration described in human plasma (65-235 
130μM) following paracetamol ingestion
30
. This could suggest that in-vitro effects may 236 
under-estimate the effects that occur in humans, however it should be emphasised that 237 
circulating paracetamol levels may not be a direct indicator of intra-testicular levels. In 238 
addition, the in-vitro models cannot mimic the pharmacokinetics, including peak and trough 239 
concentrations that occur in-vivo.   240 
 241 
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The majority of experimental studies in rodents suggest a negative association between 242 
paracetamol exposure and fetal androgen production. This has prompted subsequent in-243 
vitro studies using human fetal testis tissue. Exposure of first trimester testis (8-12 weeks 244 
gestation) to paracetamol (10 μM) for 1 to 3 days did not alter testosterone production 245 
compared to vehicle-exposed controls
39
. The differences between the results of the rodent 246 
and human in-vitro studies may relate to differences in the suitability of the in-vitro system 247 
or the timing of exposure in relation to the stage of development (including the timing of 248 
the MPW) between these two species
39
. In-vitro culture conditions cannot replicate normal 249 
human testosterone production or the in-vivo environment. To circumvent some of these 250 
limitations, an ex-vivo xenograft approach can be undertaken to investigate potential 251 
paracetamol-induced effects on the human fetal testis
79 80
. In this system, human fetal testis 252 
tissue pieces (n=5; 14-20weeks gestation) are grafted subcutaneously under the dorsal skin 253 
of castrate host nude mice. Paracetamol was then administered orally to the host animal according 254 
to a therapeutic regimen (20mg/kg; 3 times daily), resulting in a significant reduction (45%) in host 255 
serum testosterone after 7 days’ paracetamol exposure, whilst a single day’s exposure did not affect 256 
testosterone production
38
. Interestingly, plasma paracetamol concentrations, measured 1 hour after 257 
the final dose
38
 were significantly lower compared to post-therapeutic levels reported in pregnant 258 
women
72
 suggesting that the effects on testosterone can occur at clinically relevant paracetamol 259 
doses/exposures. The effect of prolonged paracetamol exposure of xenografts
38
 is in contrast to the 260 
results obtained from in-vitro culture of human fetal testis tissue
39
. This could be due to the method 261 
of delivery (media versus oral administration), timing of exposure in-vitro (8-12 weeks gestation) 262 
compared to xenografts (14-20 weeks gestation), the relative dosage, length of exposure or 263 
difference in metabolism between in-vivo and in-vitro studies. Further limitations of both the in-vitro 264 
and xenograft systems include the lack of a feto-placental unit, although it has been demonstrated 265 
that paracetamol is able to cross the placenta and enter the fetal circulation in similar 266 
concentrations to maternal plasma
72
 
73
. 267 
 268 
Overall, the results of the experimental studies suggest that exposure to paracetamol during 269 
fetal life may lead to a reduction in testosterone production in humans, although direct 270 
correlation between the degree and duration of reduced testosterone and the potential to 271 
develop male reproductive disorders cannot be made from these studies. Whilst the 272 
majority of circulating paracetamol in humans comes from ingestion of paracetamol 273 
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containing medications, an alternative source of paracetamol has also recently been 274 
described. The industrial chemical aniline, which is found in a wide variety of manufactured 275 
products e.g. pharmaceuticals, cosmetics, cigarette smoke, has been shown to be rapidly 276 
metabolised to paracetamol inside the body
81 82
. In-vivo studies involving in-utero exposure 277 
of male mice to aniline have shown similar fetal anti-androgenic effects to those described 278 
for exposure to paracetamol
77
.  279 
 280 
It is known that analgesics, including paracetamol, can inhibit prostaglandin synthesis
83
. 281 
During fetal life, g rm cells have been shown to be prostaglandin targets
84
 
85
 indicating that 282 
germ cells may also be susceptible to analgesic-induced changes, which in turn may alter GC 283 
development and fertility in the offspring. To investigate this, in-vivo studies of in-utero 284 
paracetamol exposure have been conducted in rodents
85
 
86
. In one study, pregnant rats 285 
were exposed to paracetamol (350mg/kg/d) from e15.5-18.5, which resulted in altered 286 
germ cell development in both sexes of offspring
85
. In males there was an accelerated loss 287 
of expression of a pluripotency marker (OCT4), suggesting germ cell differentiation from 288 
gonocyte to spermatogonia had occurred prematurely. It is interesting to note that the 289 
effects on germ cell differentiation in F1 males occur during the MPW, a critical period for 290 
male reproductive development
21 85
. In F1 females there was a delay in meiotic entry in 291 
oogonia. After in-utero paracetamol exposure, female offspring had reduced ovary size and 292 
exhibited reduced litter size in adulthood, whilst no reproductive effects were seen in 293 
males, suggesting a potential compensatory mechanism between fetal life and adulthood
85
. 294 
In another study, exposure of pregnant rats to a much lower dose of paracetamol 295 
(50mg/kg/d) from 7 days post-conception to birth resulted in a reduction in follicle number 296 
at 2 months postnatally and also a reduction in pups per litter at 6 months of age
86
.   297 
 298 
During fetal life, germ cells undergo epigenetic reprogramming
87
 which suggests that any 299 
perturbations to germ cells during this period could have inter-generational effects. The 300 
potential for such effects occurring following in-utero paracetamol exposure was 301 
investigated in a recent study in which paracetamol-exposed (male and female) mice were 302 
mated with a non-exposed partner. The subsequent F2 females had reduced ovary weight 303 
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(as previously described) and reduced number of primordial follicles, whilst F2 males did not 304 
appear to have any demonstrable germ cell effects
85
.  305 
 306 
Postnatal effects of paracetamol exposure on male reproductive function 307 
Whilst the majority of studies have investigated the effect of analgesic exposure on the fetal 308 
testis, one study has demonstrated that the adult testis may be susceptible to endocrine 309 
perturbations following paracetamol exposure. Explants from human adult testis (average 310 
age: 79.8 ± 5.6 years) were cultured in vitro with therapeutically relevant doses of 311 
paracetamol for 24 hours, resulting in a significant reduction in testosterone production in 312 
the presence of 10
-4
 or 10
-5
M paracetamol (30% and 18% reduction respectively)
88
. To date 313 
no studies have been conducted to assess the effect of analgesic use in adult men in terms 314 
of testosterone production or testicular function. 315 
 316 
 Analgesics are also commonly used in paediatrics; however, to our knowledge, there have 317 
been no studies investigating the effect of analgesic exposure during the neonatal, infancy 318 
or childhood period in terms of later male reproductive function. In addition, the testicular 319 
effects of exposures on babies born pre-term has not been investigated. Pharmacokinetic 320 
studies have shown that based on body weight, neonates have approximately 30% 321 
paracetamol clearance capacity compared to adults
89-91
. Exposure during the neonatal 322 
period may be of particular importance given the programmed rise in testosterone during 323 
mini-puberty
64
. Whether paracetamol exposure during this period can suppress 324 
testosterone and what the implications might be for subsequent reproductive health is 325 
unknown, although it is worth pointing out that in individuals with conditions such as 326 
hypogonadotrophic hypogonadism (in whom there is no rise in testosterone during mini 327 
puberty or at expected time of puberty), testicular function and fertility can be restored 328 
with exogenous gonadotrophins
92
. Given the relative quiescence of the HPG axis during the 329 
childhood period, it would be anticipated that the potential for anti-androgenic effects of 330 
analgesics would not be as important during this period compared to other stages 331 
throughout life; however, it is unknown whether exposures can affect Leydig, Sertoli or 332 
germ cell development during this period. Further studies are warranted to investigate the 333 
effects of exposure to analgesics during postnatal life.  334 
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Conclusion 335 
Male reproductive disorders are common and some are increasing in incidence. These 336 
disorders can be associated and linked to a reduction in testosterone during fetal life. In-337 
utero exposure to environmental agents are likely to play a role in the development of 338 
these disorders. In order to assess the potential impact of environmental agents on male 339 
reproductive function in humans, careful consideration of study methodology is required, 340 
particularly in relation to the model system and species, in addition to dose, route and 341 
duration of exposure. Effects of exposures, e.g. reduction in testosterone, must be 342 
considered in the context of the potential to result in a subsequent disorder such as 343 
cryptorchidism or reduced sperm production/counts. For in–utero paracetamol exposure, 344 
epidemiological studies demonstrate associations with cryptorchidism in the offspring, 345 
primarily in relation to exposures during the second trimester and prolonged duration of 346 
exposure, whilst experimental studies suggest that paracetamol can reduce testosterone 347 
production by the human fetal testis. Based on the current evidence discussed, it cannot 348 
be concluded that exposure to paracetamol is a direct cause of male reproductive 349 
disorders nor that analgesics should simply be avoided during pregnancy. The importance 350 
of managing pain and pyrexia during pregnancy should also be considered for the health 351 
of the mother and fetus. As a result, a pragmatic approach is to ensure that where 352 
analgesics are deemed to be necessary, that they are used at the minimum therapeutic 353 
dose for the shortest possible duration. Future studies should aim to determine the 354 
clinical relevance of the findings related to in-utero exposures, in addition to investigating 355 
the effects of exposures during postnatal life.  356 
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Figure Legends 589 
 590 
Figure 1 – In-utero factors proposed to predispose to Testicular Dysgenesis Syndrome 591 
(TDS) disorders. Many lifestyle, genetic and environmental factors during fetal life have 592 
been postulated to lead to the development of TDS disorders in male offspring, albeit with 593 
variable (and in some cases limited) sources of evidence
16
.  594 
 595 
Figure 2 – Testicular development in health and disease. Development of germ (green 596 
panel), Leydig (yellow panel) and Sertoli (purple panel) cells during different stages of 597 
testicular development. Differentiation of germ and Sertoli cells (dotted line) and the 598 
individual Leydig cell populations are shown. Note that for germ cells, failure of 599 
differentiation from gonocyte to spermatogonia leads to the development of pre-malignant 600 
Germ Cell Neoplasia In-Situ (GCNIS) cells which results in testicular germ cell cancer in young 601 
adulthood. The Masculinisation Programming Window (MPW; shaded box) is shown during 602 
fetal life in which reduced testosterone may result in the development of Testicular 603 
Dysgenesis Syndrome (TDS) disorders. Relative testosterone production 604 
during developmental periods is also indicated (black line). 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
 614 
 615 
 616 
 617 
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Tables 618 
 619 
Epidemiological 
Study Design - descriptive, case-control or experimental, relevant population 
Exposure - measured directly (agent) or indirectly (questionnaire, proxy exposure) 
Effect - direct effect (e.g. cryptorchidism) or indirect (AGD) 
Other - mechanistic plausibility for effects 
 
Experimental 
Model - species, experimental system (e.g. in-vivo, in-vitro, ex-vivo) 
Agent - same agent or similar class/compound, metabolism of agent 
Dosing - dose equivalent (e.g. serum/in-vitro concentrations), timing, duration 
Effect - direct effect (e.g. cryptorchidism) or proxy for clinical condition (AGD) 
Mechanism - e.g. effect on signalling pathways (including rescue) 
 620 
Table 1 – Key points to consider when assessing epidemiological and experimental 621 
studies relating to the effects of environmental exposures on male reproductive 622 
development.   623 
 624 
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Response to Reviewers 
 
 
Reviewer(s)' Comments to Author: 
 
Reviewer: 1 
 
Comments to the Author 
The paper is written by a research group which has been very active in research on impact of  
paracetamol on male development. It is often useful when researchers reflect on their recent results 
in an analysis of available data and put them into perspective.  While I like the discussions on 
paracetamol I feel that the general aspects of the topic, as the title seems to suggest, are somewhat 
superficially analysed. I suggest that the title 'Assessing the impact of in-utero environmental 
exposures on male reproductive function and fertility' is changed to reflect this limitation of the 
paper and focus more on paracetamol.  
 
We thank the reviewer for their helpful comments and we have taken these on board in the revised 
manuscript. It is important to bear in mind that this review was written with the ADC readership in 
mind and therefore is aimed at a general paediatric audience with the intention of introducing the 
concepts of assessing endocrine disruption using exposure to analgesics and impacts on male 
reproductive function to illustrate these points. We have however altered the text to make it clear in 
the introduction that the focus is on paracetamol (P1, Line 24; P3, Line 79-82). We have also altered 
the title to reflect this. 
 
Specific points: 
1) As the authors relate their findings to human TDS, the description of TDS seems to lack some 
important reported findings in these men, including the persistent  dysgenetic, histological 
changes in the Sertolic and Leydig cells, which can be seen in adult men with the disorder (as 
described by Rajpert-De Meyts E. Hum Reprod Update. 2006). 
 
This is an important point and we have included this in these points in the  manuscript (P 5, Line 126-
128).  
 
2) The reader may get a wrong impresion of the doses of paracetamol generally used. On page 
7, line  55 they write:' ....... however, the doses (150-350mg/kg/d) used are higher than 
human therapeutic doses (~60mg/kg/d) to which humans are usually exposed.' This 
stqatement is not correct. 60mg/kg/d is a maximal 24 h dose, only used in severe pain. 
Unfortunately, previous papers have also exaggerated the doses of paracetamol most often 
used. 
 
We respectfully disagree with this point. Paracetamol doses in children in the UK are prescribed 
according the British National Formulary. The therapeutic dose for pain/pyrexia is an initial loading 
dose of 20mg/kg and 10-15mg/kg 4-6hrly (maximum 4 doses/24 hrs). This equates to 60mg/kg/d 
and does not specifically apply to ‘severe’ pain. There may be variations in paracetamol dosing in 
different countries to which the reviewer is referring but it is reasonable to describe the stated 
doses as ‘therapeutic dosing’. In addition, in xenograft studies paracetamol levels have been directly 
measured in the serum of the host mouse and have been shown to be below those measured in the 
serum of humans following a therapeutic dose.  
 
3) Although the reader may expect from the introduction that farmaceutical paracetamol 
exposure will be discussed in relation to other exposures, mentioning of other exposures 
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e.g. exposure via secondary (non-pharmaceutical) sources, such as metabolic conversion 
from the ubiquitous industrial compound aniline are not well presented (although refences 
are mentioned). Neither  the possibility that paracetamol effects may depend on 
simultaneous exposures from environmental chemicals, e.g. phthalates, bisphenol A, and UV 
filters. 
 
As discussed this review was intended to use paracetamol as one example of how the effects of 
exposure to endocrine disruptors are assessed. We have altered the manuscript (and the title) to 
reflect the fact that we do not discuss other ‘EDCs’ in detail. We have also mentioned the concept of 
‘mixtures’ in relation to analgesic combinations (Page 7, Line 200-202). We agree that reference to 
other sources of paracetamol (e.g. aniline) is important and we have therefore included text (Page 
10, Line 274-281) to highlight this.  
 
 
4) Table 1 contains numerous important keywords of which only few are discussed. 
Furthermore it lacks a third group of studies where humans participates in endocrine studies 
with examinations of body fluids and cells (such studies are not just 'epidemiological').  
Either the table legend should be expanded or the table deleted and replaced with a couple 
of sentences. 
  
We agree that ‘clinical studies’ involving human participants are important approaches to the study 
of environmental and pharmaceutical exposures. However, they can still be broadly classified either 
as an ‘experimental’ or ‘epidemiological’ study depending on whether an intervention 
(experimental) was involved. Descriptive studies relating to exposures (including measured levels in 
bodily fluids) and associations with clinical outcomes etc can be classified as epidemiological studies. 
We have made some adjustments to the legend and discussed these factors throughout  the text. 
 
5) Table 2 is also difficualt for an outsider to understand. It needs much more explanation 
(meaning of crosses?) and two symbols in a box is difficult to understand. The text should be 
expanded. 
 
We agree that Table 2 will be difficult to understand so we have deleted the table. The points raised 
in the table are discussed throughout the text. 
 
6) Fig 1. is somewhat misleading. If the authors believe that over/undernutrition  can cause 
TDS they should include data. Anti-androgenic and estrogenic chemicals are mentioned. 
However, this whole field of endocrine dsirupters has expanded during the past 10 years. 
The figure text could perhaps be used in a high school text book, but not in a scientific 
journal as Archives of Diseases in Childhood. 
 
We agree that the list of ‘potential’ endocrine disruptors has increased dramatically over recent 
years and that this should be reflected in the text of the figure and we have modified this 
accordingly. The purpose of this introductory figure is simply to get across to a primarily general 
paediatric audience the idea that many exposures from a variety of different sources have been 
implicated as playing a role in the development of TDS disorders. We use ?? to highlight the fact that 
for many of these exposures their role in the development of TDS is still not clear.  
 
7) Fig. 2 is somewhat confusing. The link between the gonocyte and germ cell cancer is not 
easy to spot. The group has previously produced TDS figures which were more helpful. 
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This figure is intended to describe testicular development across the lifecourse rather than to focus 
completely on mechanisms relating to TDS, hence the differences compared to our previously 
published figures on TDS origins and mechanisms. We refer to publications relating to TDS in which 
such figures are available. We agree with the reviewer that the relationship between gonocyte and 
GCNIS/TGCC is not illustrated in the current figure and we have modified the figure to explain this 
concept. 
  
 
 
Reviewer: 2 
 
Comments to the Author 
This is a well written review and I have very few comments because of the quality of the writing and  
content 
 
We thank the reviewer for the positive comments. 
 
Page 3, line 14 – do the authors mean technical or practical difficulties? – presumably they simply 
mean that measuring this distance is embarrassing and not acceptable to humans? Is that correct? 
 
The measurement of AGD is technically difficult in terms of accuracy of measurement and 
reproducibility as it depends on the expertise of the examiner and also requires accurate calibrated 
equipment. Practical difficulties relate to time required to measure and acceptability to patients in 
addition to clinical applicability for individual patients. We have modified this sentence to account 
for this (Page 3, Line 66-69).  
 
Page 8, line 15 – presumably one form of exposure (in vitro) is continuous whereas in human plasma 
there are peaks and troughs? 
 
This is correct and we have made reference to this in the text (Page 8, Line 238-242). 
 
I think that using paracetamol as an illustration of the issues involved generally works. However the 
discussions are primarily about paracetamol and testosterone – which is (it can be argued) not of 
greatest interest because many of its’ key effects occur following conversion to dihydrotestosterone 
or oestrogen. Could the authors discuss or comment? 
 
It is true that DHT mediates some of the key masculinising effects in the male (e.g. external 
genitalia); however it is clear from rodent studies and clinical conditions that reductions in 
testosterone can result in TDS-like and masculinisation disorders which reflects the fact that 
testosterone is the primary precursor for DHT and oestrogen. Previous in-vivo rodent studies, 
investigating the effect of blocking both testosterone and DHT (via flutamide) in male fetuses results 
in subnormal AGD which correlates with incidence and severity of hypospadias, cryptorchidism, and 
reduced phallus length and seminal vesicle weight in males (Welsh et al 2008). We initially refer to 
androgens which would include DHT and testosterone, before focusing on testosterone which is 
known to be important for testicular descent.  
 
I did wonder if readers would find a table listing the key agents that have been implicated in the 
evolution of disorders of reproduction / fertility of value . 
 
We have increased the list in Figure 1 of EDCs that have been proposed to cause TDS disorders in 
response to this comment and that of Reviewer 1.   
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Page 11 line 10 – some are increasing…(remove ‘at least’) 
 
This has been removed as requested. 
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Epidemiological 
Study Design - descriptive, case-control or experimental, relevant population 
Exposure - measured directly (agent) or indirectly (questionnaire, proxy exposure) 
Effect - direct effect (e.g. cryptorchidism) or indirect (AGD) 
Other - mechanistic plausibility for effects 
 
Experimental 
Model - species, experimental system (e.g. in-vivo, in-vitro, ex-vivo) 
Agent - same agent or similar class/compound, metabolism of agent 
Dosing - dose equivalent (e.g. serum/in-vitro concentrations), timing, duration 
Effect - direct effect (e.g. cryptorchidism) or proxy for clinical condition (AGD) 
Mechanism - e.g. effect on signalling pathways (including rescue) 
 
Table 1 – Key points to consider when assessing epidemiological and experimental studies 
relating to the effects of environmental exposures on male reproductive development.   
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Lifestyle Factors
Genetics
Environmental exposures
TDS Disorders
??
Cryptorchidism
Hypospadias
Testicular Germ
Cell Cancer
Low Sperm Count
Primary Hypogonadism
Maternal smoking/
alcohol consumption
Sedentary work/lifestyle
Over/under nutrition
Stress
Genetic Mutations
Epigenetic Factors
Fetal Growth
Pharmaceuticals
e.g. analgesics
Endocrine disrupting 
chemicals/anti-androgenic 
or estrogenic:
Pesticides
Phthalates
Dioxins 
Peruorinated compounds  
Ultraviolet lters
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Adult LC
Leydig cells
Neonatal LC
Gestation 
Presumptive MPW
Reduced
Testosterone
Cryptorchidism
Hypospadias
Primary HypogonadismTestis Germ Cell Cancer
Testis Germ Cell Cancer
TDS Disorders
Low Sperm Count
Spermatocytes Sperm
Mature SC
Gonocyte
GCNIS
Immature SC Immature SC
Birth Infancy Puberty Adulthood
Germ cells
Sertoli cells
Immature SC
Testosterone
Spermatogonia
Fetal LC
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